Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/1999

01-02-1999 | ORIGINAL ARTICLE

Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit

Authors: Philip Kestell, James W. Paxton, Gordon W. Rewcastle, Ingrid Dunlop, Bruce C. Baguley

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/1999

Login to get access
Metadata
Title
Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit
Authors
Philip Kestell
James W. Paxton
Gordon W. Rewcastle
Ingrid Dunlop
Bruce C. Baguley
Publication date
01-02-1999
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/1999
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800050902

Other articles of this Issue 4/1999

Cancer Chemotherapy and Pharmacology 4/1999 Go to the issue

ORIGINAL ARTICLE

Pharmacokinetic analysis and antitumor efficacy of MKT-077, a novel antitumor agent

ORIGINAL ARTICLE

Etoposide enhances the lethal effect of radiation on breast cancer cells with less damage to mammary gland cells

ORIGINAL ARTICLE

Polyamine analog bis(ethylamino)-5,10,15-triazanonadecane (BE-4-4-4-4) enhances simian virus 40 late gene expression

ORIGINAL ARTICLE

Pharmacokinetics of the green tea derivative, EGCG, by the topical route of administration in mouse and human skin

SHORT COMMUNICATION

Expression of GADD153 in tumor cells and stromal cells from xenografted tumors in nude mice treated with cisplatin: correlations with cisplatin-DNA adducts

ORIGINAL ARTICLE

Relationship between tumor extracellular fluid exposure to topotecan and tumor response in human neuroblastoma xenograft and cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits